source
- Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data🩻 Angitia Biopharmaceuticals drops Phase 3: The US and China biotech terminated a late-stage trial of AGA111 in patients with degenerative disc disease who had a lumbar interbody fusion, according…Endpoints · 29d ago↗ source
- Ipsen to scoop up Memo Therapeutics and its kidney infection drugIpsen is on an M&A roll. The French drugmaker announced its second deal of the week, saying it would buy Memo Therapeutics and its drug candidate called potravitug for a viral ...Endpoints · 29d ago↗ source
- A June flourish lifts biotech megaround tally in first half of 2026Forty private biotech companies disclosed funding rounds of $100 million or more in the first half of 2026, according to an Endpoints News tally. That's more than the same period of 2025 ...